Mark Creighton-Gutteridge

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses<i>In Vivo</i>

Rocío Montes de, Alireza Alavi, Nick Vitali et al. · Molecular Cancer Therapeutics · 2021 · 111 citations · Full text

Life Sciences, Immunology, Oncology +17

Synergystic induction of HIF-1α transcriptional activity by hypoxia and lipopolysaccharide in macrophages

Zenghui Mi, Annamaria Rapisarda, Lynn S. Taylor et al. · Cell Cycle · 2008 · 61 citations · Full text

Life Sciences, Immunology, Molecular Biology +16

Cell Type–Specific, Topoisomerase II–Dependent Inhibition of Hypoxia-Inducible Factor-1α Protein Accumulation by NSC 644221

Mark Creighton-Gutteridge, John H. Cardellina, Andrew G. Stephen et al. · Clinical Cancer Research · 2007 · 51 citations

Medicine, Medicinal Chemistry, Pharmacology +13

A novel iron chelator that does not induce HIF-1 activity

Mark Creighton-Gutteridge, Rex M. Tyrrell · Free Radical Biology and Medicine · 2002 · 32 citations

Medicine, Biochemistry, Pharmacology +11

PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY

Rocío Montes de, Sabyasachi Bhattacharya, Nick Vitali et al. · HemaSphere · 2019 · 17 citations · Full text

Medicine, Immunology, Oncology +17